• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

针对肿瘤坏死因子受体超家族进行癌症免疫治疗。

Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.

作者信息

Bremer Edwin

机构信息

Department of Surgery, Translational Surgical Oncology, University Medical Center Groningen, University of Groningen, 9713GZ Groningen, The Netherlands.

出版信息

ISRN Oncol. 2013 Jun 11;2013:371854. doi: 10.1155/2013/371854. Print 2013.

DOI:10.1155/2013/371854
PMID:23840967
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3693168/
Abstract

The tumor necrosis factor (TNF) ligand and cognate TNF receptor superfamilies constitute an important regulatory axis that is pivotal for immune homeostasis and correct execution of immune responses. TNF ligands and receptors are involved in diverse biological processes ranging from the selective induction of cell death in potentially dangerous and superfluous cells to providing costimulatory signals that help mount an effective immune response. This diverse and important regulatory role in immunity has sparked great interest in the development of TNFL/TNFR-targeted cancer immunotherapeutics. In this review, I will discuss the biology of the most prominent proapoptotic and co-stimulatory TNF ligands and review their current status in cancer immunotherapy.

摘要

肿瘤坏死因子（TNF）配体和同源TNF受体超家族构成了一个重要的调节轴，这对于免疫稳态和免疫反应的正确执行至关重要。TNF配体和受体参与了多种生物学过程，从在潜在危险和多余细胞中选择性诱导细胞死亡到提供共刺激信号以帮助产生有效的免疫反应。这种在免疫中多样且重要的调节作用引发了人们对开发靶向TNFL/TNFR的癌症免疫疗法的极大兴趣。在这篇综述中，我将讨论最突出的促凋亡和共刺激TNF配体的生物学特性，并回顾它们在癌症免疫治疗中的现状。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/da48cb855d85/ISRN.ONCOLOGY2013-371854.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/8ba4e400bcf4/ISRN.ONCOLOGY2013-371854.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/16575feb50db/ISRN.ONCOLOGY2013-371854.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/93a668b4c605/ISRN.ONCOLOGY2013-371854.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/1f99ff967609/ISRN.ONCOLOGY2013-371854.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/f79a8724962d/ISRN.ONCOLOGY2013-371854.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/6a5601b10769/ISRN.ONCOLOGY2013-371854.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/a678bf64c01c/ISRN.ONCOLOGY2013-371854.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/f36155ebe88c/ISRN.ONCOLOGY2013-371854.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/da48cb855d85/ISRN.ONCOLOGY2013-371854.009.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/8ba4e400bcf4/ISRN.ONCOLOGY2013-371854.001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/16575feb50db/ISRN.ONCOLOGY2013-371854.002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/93a668b4c605/ISRN.ONCOLOGY2013-371854.003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/1f99ff967609/ISRN.ONCOLOGY2013-371854.004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/f79a8724962d/ISRN.ONCOLOGY2013-371854.005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/6a5601b10769/ISRN.ONCOLOGY2013-371854.006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/a678bf64c01c/ISRN.ONCOLOGY2013-371854.007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/f36155ebe88c/ISRN.ONCOLOGY2013-371854.008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/de4c/3693168/da48cb855d85/ISRN.ONCOLOGY2013-371854.009.jpg

相似文献

1
Targeting of the tumor necrosis factor receptor superfamily for cancer immunotherapy.针对肿瘤坏死因子受体超家族进行癌症免疫治疗。
ISRN Oncol. 2013 Jun 11;2013:371854. doi: 10.1155/2013/371854. Print 2013.
2
Structural and biological features of the TNF receptor and TNF ligand superfamilies: interactive signals in the pathobiology of Hodgkin's disease.肿瘤坏死因子受体和肿瘤坏死因子配体超家族的结构与生物学特性：霍奇金病病理生物学中的交互信号
Ann Oncol. 1996;7 Suppl 4:19-26. doi: 10.1093/annonc/7.suppl_4.s19.
3
Tumor necrosis factor ligand superfamily: involvement in the pathology of malignant lymphomas.肿瘤坏死因子配体超家族：参与恶性淋巴瘤的病理学过程。
Blood. 1995 Jun 15;85(12):3378-404.
4
The TNF-TNFR Family of Co-signal Molecules.肿瘤坏死因子-肿瘤坏死因子受体家族共刺激分子。
Adv Exp Med Biol. 2019;1189:53-84. doi: 10.1007/978-981-32-9717-3_3.
5
Analysis of Ligand-Receptor Interactions Using Bioluminescent TNF Superfamily (TNFSF) Ligand Fusion Proteins.利用生物发光 TNF 超家族（TNFSF）配体融合蛋白分析配体-受体相互作用。
Methods Mol Biol. 2021;2248:185-200. doi: 10.1007/978-1-0716-1130-2_13.
6
Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.用于实体瘤免疫治疗的细胞因子、趋化因子和共刺激融合蛋白。
Handb Exp Pharmacol. 2008(181):291-328. doi: 10.1007/978-3-540-73259-4_13.
7
Receptor Oligomerization and Its Relevance for Signaling by Receptors of the Tumor Necrosis Factor Receptor Superfamily.受体寡聚化及其与肿瘤坏死因子受体超家族受体信号传导的相关性。
Front Cell Dev Biol. 2021 Feb 11;8:615141. doi: 10.3389/fcell.2020.615141. eCollection 2020.
8
A Systematic Test of Receptor Binding Kinetics for Ligands in Tumor Necrosis Factor Superfamily by Computational Simulations.通过计算模拟对肿瘤坏死因子超家族配体的受体结合动力学进行系统测试。
Int J Mol Sci. 2020 Mar 5;21(5):1778. doi: 10.3390/ijms21051778.
9
Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy.针对 TNF 超家族共刺激受体的癌症免疫疗法。
BioDrugs. 2023 Jan;37(1):21-33. doi: 10.1007/s40259-022-00573-3. Epub 2022 Dec 26.
10
Delivering co-stimulatory tumor necrosis factor receptor agonism for cancer immunotherapy: past, current and future perspectives.提供共刺激肿瘤坏死因子受体激动剂用于癌症免疫治疗：过去、现在和未来的观点。
Front Immunol. 2023 Apr 25;14:1147467. doi: 10.3389/fimmu.2023.1147467. eCollection 2023.

引用本文的文献

1
Effects of DNA Origami-Based Nanoagent Design on Apoptosis Induction in a Large 3D Cancer Spheroid Model.基于DNA折纸的纳米制剂设计对大型三维癌症球体模型中细胞凋亡诱导的影响。
Small. 2025 Jun;21(24):e2502490. doi: 10.1002/smll.202502490. Epub 2025 Apr 25.
2
Advanced multiparametric image spectroscopy and super-resolution microscopy reveal a minimal model of CD95 signal initiation.高级多参数图像光谱学和超分辨率显微镜揭示了 CD95 信号起始的最小模型。
Sci Adv. 2024 Aug 30;10(35):eadn3238. doi: 10.1126/sciadv.adn3238.
3
Adapting Ferritin, a Naturally Occurring Protein Cage, to Modulate Intrinsic Agonism of OX40.

本文引用的文献

1
The role of soluble CD40L in immunosuppression.可溶性CD40L在免疫抑制中的作用。
Oncoimmunology. 2013 Jan 1;2(1):e22546. doi: 10.4161/onci.22546.
2
Death signalobody: inducing conditional cell death in response to a specific antigen.死亡信号体：响应特定抗原诱导条件性细胞死亡。
Hum Gene Ther Methods. 2013 Jun;24(3):141-50. doi: 10.1089/hgtb.2012.147. Epub 2013 Apr 21.
3
The additional facet of immunoscore: immunoprofiling as a possible predictive tool for cancer treatment.免疫评分的附加方面：免疫分析作为癌症治疗的一种潜在预测工具。
改造天然存在的蛋白笼铁蛋白，调节 OX40 的内在激动性。
Bioconjug Chem. 2024 May 15;35(5):593-603. doi: 10.1021/acs.bioconjchem.4c00020. Epub 2024 Apr 9.
4
Design and selection of anti-PD-L1 single-domain antibody and tumor necrosis factor superfamily ligands for an optimal vectorization in an oncolytic virus.用于溶瘤病毒中最佳载体化的抗PD-L1单域抗体和肿瘤坏死因子超家族配体的设计与选择
Front Bioeng Biotechnol. 2023 Nov 15;11:1247802. doi: 10.3389/fbioe.2023.1247802. eCollection 2023.
5
Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy.嵌合抗原受体自然杀伤细胞：一种有前景的抗肿瘤免疫疗法。
MedComm (2020). 2023 Dec 1;4(6):e422. doi: 10.1002/mco2.422. eCollection 2023 Dec.
6
EGFR-selective activation of CD27 co-stimulatory signaling by a bispecific antibody enhances anti-tumor activity of T cells.双特异性抗体选择性激活 EGFR 共刺激信号 CD27，增强 T 细胞的抗肿瘤活性。
Front Immunol. 2023 Jul 20;14:1191866. doi: 10.3389/fimmu.2023.1191866. eCollection 2023.
7
Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.工程化可溶性三聚体 4-1BBL 变体作为有效的免疫调节剂。
Cancer Immunol Immunother. 2023 Sep;72(9):3029-3043. doi: 10.1007/s00262-023-03474-8. Epub 2023 Jun 13.
8
Engineering of a trispecific tumor-targeted immunotherapy incorporating 4-1BB co-stimulation and PD-L1 blockade.工程化三联特异性肿瘤靶向免疫疗法，包含 4-1BB 共刺激和 PD-L1 阻断。
Oncoimmunology. 2021 Dec 2;10(1):2004661. doi: 10.1080/2162402X.2021.2004661. eCollection 2021.
9
Molecular Mechanisms of Tumor Immunomodulation in the Microenvironment of Colorectal Cancer.结直肠癌微环境中肿瘤免疫调节的分子机制。
Int J Mol Sci. 2022 Mar 3;23(5):2782. doi: 10.3390/ijms23052782.
10
Over Fifty Years of Life, Death, and Cannibalism: A Historical Recollection of Apoptosis and Autophagy.五十余载生生死死，从凋亡到自噬：对细胞自噬现象的历史回顾。
Int J Mol Sci. 2021 Nov 18;22(22):12466. doi: 10.3390/ijms222212466.
J Transl Med. 2013 Mar 3;11:54. doi: 10.1186/1479-5876-11-54.
4
Clinical targeting of the TNF and TNFR superfamilies.TNF 和 TNFR 超家族的临床靶向治疗。
Nat Rev Drug Discov. 2013 Feb;12(2):147-68. doi: 10.1038/nrd3930. Epub 2013 Jan 21.
5
Functional characterization of a chimeric soluble Fas ligand polymer with in vivo anti-tumor activity.具有体内抗肿瘤活性的嵌合可溶性 Fas 配体聚合物的功能特征。
PLoS One. 2013;8(1):e54000. doi: 10.1371/journal.pone.0054000. Epub 2013 Jan 9.
6
Enhanced function of cytotoxic T lymphocytes induced by dendritic cells modified with truncated PSMA and 4-1BBL.树突状细胞修饰的截短 PSMA 和 4-1BBL 增强细胞毒性 T 淋巴细胞的功能。
Hum Vaccin Immunother. 2013 Apr;9(4):766-72. doi: 10.4161/hv.23116. Epub 2013 Jan 7.
7
A converse 4-1BB and CD40 ligand expression pattern delineates activated regulatory T cells (Treg) and conventional T cells enabling direct isolation of alloantigen-reactive natural Foxp3+ Treg.一种相反的 4-1BB 和 CD40 配体表达模式划定了激活的调节性 T 细胞（Treg）和常规 T 细胞，从而能够直接分离同种抗原反应性天然 Foxp3+Treg。
J Immunol. 2012 Dec 15;189(12):5985-94. doi: 10.4049/jimmunol.1201090. Epub 2012 Nov 16.
8
Increased apoptosis induction in hepatocellular carcinoma by a novel tumor-targeted TRAIL fusion protein combined with bortezomib.新型肿瘤靶向 TRAIL 融合蛋白联合硼替佐米诱导肝癌细胞凋亡增加。
Hepatology. 2013 Feb;57(2):625-36. doi: 10.1002/hep.26082. Epub 2013 Jan 8.
9
Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role.癌症患者血清可溶性 CD40 配体升高可能发挥免疫抑制作用。
Blood. 2012 Oct 11;120(15):3030-8. doi: 10.1182/blood-2012-05-427799. Epub 2012 Aug 28.
10
SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ.SA-4-1BBL 共刺激通过产生 IFN-γ抑制常规 CD4+T 细胞向 CD4+FoxP3+T 调节细胞的转化。
PLoS One. 2012;7(8):e42459. doi: 10.1371/journal.pone.0042459. Epub 2012 Aug 1.